Imbio PHA (4.0.0) vs EchoNext
AI Verdict
Choose Imbio PHA (4.0.0) if…
Choose Imbio PHA (4.0.0) if your clinical workflow involves analyzing CT pulmonary angiogram (CTPA) scans for patients with suspected pulmonary embolism or hypertension. This tool excels at rapidly and automatically measuring cardiac structures like right and left ventricle diameters, and main pulmonary artery and aorta diameters, providing crucial RV/LV and PA/Ao ratios to aid in diagnosis and risk stratification. It integrates seamlessly into existing DICOM workflows and delivers annotated images and summary reports, making it ideal for radiologists and cardiologists needing quick, quantitative assessments from CTPA data.
View Imbio PHA (4.0.0) →Choose EchoNext if…
Choose EchoNext if you need a non-invasive, AI-powered screening tool to detect hidden structural heart disease from standard ECGs in a broad patient population. This tool is particularly well-suited for primary care, family medicine, or hospital medicine settings where routine ECGs are performed, and there's a need to identify patients at risk for conditions like heart failure, valve disease, or pulmonary hypertension who may require further cardiac ultrasound evaluation. EchoNext offers a cost-effective and accessible way to enhance early detection and streamline referrals for more advanced diagnostics.
View EchoNext →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Imbio PHA (4.0.0) | EchoNext |
|---|---|---|
| Pricing | Contact for pricing | Starts at $600/month |
| Deployment | Cloud, Enterprise (on-premise), or via partners | Available through the OpenEvidence clinical decision support platform. |
| BAA Available | Unknown | Yes AI-estimated |
| FDA Status | Yes AI-estimated | Yes AI-estimated |
| HIPAA | Unknown | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Imbio PHA (4.0.0)Imbio PHA emphasizes a 'fully automated' and 'no user interfaces to learn' approach, integrating seamlessly into existing DICOM workflows and PACS without requiring active user intervention for analysis. This 'zero-click' functionality provides a highly streamlined experience for radiologists. EchoNext, while available through a clinical decision support platform, doesn't explicitly highlight the same level of automated, 'zero-click' integration within existing imaging workflows.
Clinical Value
EchoNextBoth tools are FDA-cleared and offer significant clinical value within their respective domains. However, EchoNext has demonstrated superior diagnostic accuracy compared to expert cardiologists in multiple validation studies, even when cardiologists were assisted by AI. It has also been credited with detecting previously undiagnosed heart failure leading to a heart transplant, showcasing a direct and impactful clinical outcome.
Pricing & Value
EchoNextEchoNext offers transparent tiered pricing starting at $600/month, with details on implementation fees and annual discounts, providing a clear understanding of costs. Imbio PHA, in contrast, requires users to 'contact for pricing,' which offers less upfront clarity for potential customers.
Enterprise Readiness
TieBoth tools demonstrate strong enterprise readiness. Imbio PHA offers flexible deployment options (Cloud, Enterprise on-premise, or via partners) and is third-party certified for HIPAA compliance. EchoNext is designed for broad access, from major hospitals to community practices, and is available through the OpenEvidence clinical decision support platform, which is used by 650,000 U.S. physicians.
Innovation
EchoNextEchoNext represents a significant innovation by enabling the detection of hidden structural heart disease from standard, inexpensive ECGs, a capability traditionally not associated with ECGs. This has the potential to create an entirely new screening paradigm for heart disease. Imbio PHA's innovation lies in automating complex CTPA analysis, which is valuable but builds upon an existing imaging modality.
Support & Docs
TieNeither product's provided information or web search results offer specific details about the depth or breadth of their support and documentation beyond general statements. Therefore, it is not possible to definitively pick a winner in this dimension.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Imbio PHA (4.0.0) | EchoNext |
|---|---|---|
| Tool Name | Imbio PHA (4.0.0) | EchoNext |
| Company | Imbio | Pathway Labs |
| Description | FDA-cleared AI-powered medical image processing software that automatically measures cardiac structures from CT pulmonary angiogram (CTPA) scans to assess potential right ventricular dilation and aid in the diagnosis and risk stratification of pulmonary embolism and hypertension. | FDA-cleared AI tool from Pathway Labs that analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension. |
| Key Features | Automated measurement of right and left ventricle diameters; Automated measurement of main pulmonary artery and aorta diameters; Calculates RV/LV and PA/Ao ratios; Utilizes artificial intelligence algorithms for anatomical identification and measurement; Generates annotated DICOM images; Provides summary reports in PDF format; Integrates with native DICOM tools and workflows; Rapid, fully-automated assessment (typically in minutes) | AI-powered ECG analysis; Detection of hidden structural heart disease; Identifies heart failure risk; Screens for valve disease; Detects pulmonary hypertension indicators; Utilizes standard 12-lead ECGs; FDA-cleared technology; Non-invasive diagnostic support |
Videos
Demos, reviews, and walkthroughs featuring Imbio PHA (4.0.0) and EchoNext.